Company intelligence / Profile preview
Samaritan Pharmaceuticals, Inc.
Las Vegas, Nevada, United Statessamaritanpharma.com ↗
- Ownership
- Private
- Employees
- ~50
- Development stage
- Other
01
Overview
The company had several drug candidates in development, including SP-01A (HIV entry inhibitor) which showed viral load reduction in Phase II trials, and Caprospinol (SP-233) for Alzheimer's which received an IND from the FDA for Phase I studies. However, all programs appear to have been discontinued.
- Therapeutic areas
- OncologyCardiovascularNeurologyInfectious Diseases
- Modalities
- Small moleculespeptides
- Industry
- Biotech
02
Drug pipeline
3 assets2 more assets in the full pipeline.
03
Partnerships
PharmaplazTaconic FarmsEUSA PharmaShire Human GeneticAbiogen PharmaMolteni PharmaceuticalsONYThree Rivers Pharmaceuticals
Beyond the preview
Go deeper on Samaritan Pharmaceuticals, Inc..
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Follow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Explore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Trace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Compare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Explore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Connect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Samaritan Pharmaceuticals, Inc..